{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:04:38Z","timestamp":1783184678672,"version":"3.54.6"},"reference-count":36,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myeloid\/lymphoid neoplasms with FGFR1 rearrangement (M\/LN-FGFR1) are rare, heterogenous diseases due to fusion transcripts originated by translocations of FGFR1 with different partners, resulting in constitutive FGFR1-mediated signaling. Presentation varies from chronic myeloid neoplasms to acute leukemia or lymphoma and extramedullary localizations are common. Outside allogeneic stem cell transplantation, survival with conventional therapy is dismal, representing an unmet clinical need. We summarize here the data that led to approval of pemigatinib, a FGFR1 inhibitor, showing unprecedented efficacy in M\/LN-FGFR1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031016","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:28:46Z","timestamp":1772648926000},"page":"2171-2175","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Myeloid\/lymphoid neoplasms with\n                    <i>FGFR1<\/i>\n                    rearrangement and pemigatinib"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"first","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6899-7570","authenticated-orcid":false,"given":"Jay L.","family":"Patel","sequence":"additional","affiliation":[{"name":"2Huntsman Cancer Institute and ARUP Laboratories, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"3Clinical Investigation Center, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, INSERM, Universit\u00e9 Paris Cit\u00e9, Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2026050711214961800_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026050711214961800_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2026050711214961800_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"issue":"16","key":"2026050711214961800_bib4","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.2023022417","article-title":"How I diagnose and treat myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions","volume":"145","author":"Reiter","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026050711214961800_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V86.2.834.bloodjournal862834","article-title":"Myeloproliferative disorder associated with 8p11 translocations","volume":"86","author":"Aguiar","year":"1995","journal-title":"Blood"},{"issue":"4","key":"2026050711214961800_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/gcc.2870120408","article-title":"Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 Mbp region of chromosome 13","volume":"12","author":"Kempski","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"2026050711214961800_bib7","first-page":"1628","article-title":"A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review","volume":"9","author":"Macdonald","year":"1995","journal-title":"Leukemia"},{"key":"2026050711214961800_bib8","doi-asserted-by":"crossref","first-page":"1015792","DOI":"10.3389\/fonc.2022.1015792","article-title":"The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"2026050711214961800_bib9","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41375-023-01958-1","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort","volume":"37","author":"Metzgeroth","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026050711214961800_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2026050711214961800_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000546910","article-title":"Identification and confirmation of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement and characterization of treatment patterns and outcomes in a real-world setting: a US retrospective chart review","author":"Parasuraman","year":"2025","journal-title":"Acta Haematol"},{"issue":"4","key":"2026050711214961800_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/PAP.0000000000000486","article-title":"An approach to the bone marrow workup and diagnosis of eosinophilia and mast cell disorders","volume":"32","author":"Reichard","year":"2025","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"2026050711214961800_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ajcp\/aqaf008","article-title":"High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: the reference laboratory perspective","volume":"164","author":"Shean","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"21","key":"2026050711214961800_bib14","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2026050711214961800_bib15","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V98.13.3778","article-title":"The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins","volume":"98","author":"Demiroglu","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2026050711214961800_bib16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/gcc.21973","article-title":"Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome","volume":"51","author":"Li","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"2026050711214961800_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","article-title":"Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase","volume":"65","author":"Montenegro-Garreaud","year":"2017","journal-title":"Hum Pathol"},{"issue":"7","key":"2026050711214961800_bib18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026050711214961800_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/16078454.2020.1854493","article-title":"Myeloid\/lymphoid neoplasm with CEP110-FGFR1 fusion: an analysis of 16 cases show common features and poor prognosis","volume":"26","author":"Chen","year":"2021","journal-title":"Hematology"},{"issue":"5","key":"2026050711214961800_bib20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-023-01859-3","article-title":"Comprehensive response criteria for myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group","volume":"37","author":"Shomali","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2026050711214961800_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","article-title":"Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement","volume":"23","author":"Umino","year":"2018","journal-title":"Hematology"},{"issue":"4","key":"2026050711214961800_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1634\/theoncologist.2016-0354","article-title":"Response to tyrosine kinase inhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1 rearrangement","volume":"22","author":"Wehrli","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"2026050711214961800_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41409-021-01553-x","article-title":"Allogeneic hematopoietic cell transplantation in patients with myeloid\/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT","volume":"57","author":"Hern\u00e1ndez-Boluda","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"2026050711214961800_bib24","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.2024028000","article-title":"Role of allo-HCT in \u201cnonclassical\u201d MPNs and MDS\/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT","volume":"145","author":"Polverelli","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2026050711214961800_bib25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"issue":"9","key":"2026050711214961800_bib26","doi-asserted-by":"crossref","first-page":"EVIDoa2500017","DOI":"10.1056\/EVIDoa2500017","article-title":"Pemigatinib for myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"4","author":"Verstovsek","year":"2025","journal-title":"NEJM Evid"},{"issue":"6","key":"2026050711214961800_bib27","doi-asserted-by":"crossref","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"2026050711214961800_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026050711214961800_bib29","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026050711214961800_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026050711214961800_bib31","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026050711214961800_bib32","doi-asserted-by":"crossref","first-page":"EVIDoa2500017","DOI":"10.1056\/EVIDoa2500017","article-title":"Pemigatinib for myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"4","author":"Verstovsek","year":"2025","journal-title":"NEJM Evid"},{"issue":"4","key":"2026050711214961800_bib33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFR\u03b1 T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026050711214961800_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"2026050711214961800_bib35","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"2026050711214961800_bib36","doi-asserted-by":"crossref","first-page":"101204","DOI":"10.1016\/j.xcrm.2023.101204","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2171\/2517407\/blood_bld-2025-031016-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2171\/2517407\/blood_bld-2025-031016-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:22:02Z","timestamp":1778167322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/19\/2171\/566918\/Myeloid-lymphoid-neoplasms-with-FGFR1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031016","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,7]]},"published":{"date-parts":[[2026,5,7]]}}}